The State Street SPDR S&P Biotech ETF (XBI) is designed to closely track the total return performance of the S&P Biotechnology Select Industry Index, prior to accounting for fees and expenses. Its primary objective is to offer investors targeted exposure exclusively to the biotechnology segment of the market. A distinguishing characteristic is its underlying modified equal-weighted index, which fosters a diversified portfolio by ensuring balanced representation across large, mid, and small-capitalization biotech companies, thereby minimizing concentration risk. This structure makes XBI a precise tool for investors seeking to implement strategic or tactical allocations within the biotech sector, providing a more focused investment approach compared to traditional, broader sector funds.

Travere Therapeutics, Inc.

TG Therapeutics, Inc.

Twist Bioscience Corporation

Revolution Medicines, Inc.

Alkermes plc

Arrowhead Pharmaceuticals, Inc.

Krystal Biotech, Inc.

Exelixis, Inc.

Nuvalent, Inc.

Neurocrine Biosciences, Inc.

Healthcare

Financial Services

SPDR® S&P Biotech ETF

XBI Holdings & Sector Breakdown

XBI Holdings & Sector Breakdown